Serial Immunohematological Monitoring of ABO Blood Group Conversion Following Fully Human Leukocyte Antigen-matched Bidirectional ABO-incompatible Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report
Year: 2026
Type: article
Study design: Case Report
Abstract: Background: ABO-incompatibility in allogeneic hematopoietic stem cell transplantation (HSCT) is common and does not constitute a contraindication to transplantation.However, bidirectional ABO-incompatibility presents unique immunohematological challenges because both recipient-and donor-derived isoagglutinins may influence erythroid engraftment, immune reconstitution, transfusion support, and ABO blood group conversion.Serial immunohematological monitoring is therefore essential to ensure safe transfusion management and document successful donor-type blood group conversion.We report a case of a fully human leukocyte antigen (HLA)-matched bidirectional ABO-incompatible allogeneic HSCT and demonstrate the sequential kinetics of recipient-derived anti-B and donor-derived anti-A isoagglutinins during donor erythroid and immune engraftment.Case description: We report a case of a fully HLA-matched bidirectional ABO-incompatible allogeneic HSCT in which an A Rh-positive recipient underwent transplantation from a B Rh-positive donor.Pretransplant isoagglutinin titers were assessed, and serial post-transplant immunohematological monitoring was performed according to departmental standard operating procedures (SOPs) using conventional test tube techniques, including forward and reverse ABO grouping, direct antiglobulin testing (DAT), antibody screening, and IgM and IgG isoagglutinin titration.A gradual decline in recipient-derived anti-B isoagglutinin titers was observed, followed by progressive donor-type red cell engraftment.Mixed-field agglutination was observed by day 60, donor-derived anti-A isoagglutinins appeared by day 90, and complete donor-type ABO blood group conversion with sustained immune reconstitution was documented by day 150.No clinically significant hemolysis, pure red cell aplasia (PRCA), or transfusion-related complications were observed.Transfusion support was provided using phase-appropriate ABO-compatible blood components tailored to the evolving donor-recipient serological profile until complete donor-type conversion was achieved.Conclusion: This case highlights the importance of comprehensive serial immunohematological monitoring in bidirectional ABO-incompatible HSCT.Sequential assessment of ABO blood grouping and reciprocal isoagglutinin titers enables accurate documentation of donor erythroid engraftment, immune reconstitution, and successful donor-type blood group conversion while facilitating safe transfusion management.Clinical significance: Serial immunohematological monitoring, including forward and reverse ABO grouping and sequential IgM and IgG isoagglutinin titration, provides a practical approach for documenting donor erythroid and immune engraftment, optimizing phase-appropriate transfusion support, and minimizing transfusion-related complications following bidirectional ABO-incompatible allogeneic HSCT.
Language: English
Topic: Blood groups and transfusion
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7237202136
